SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen® Versus Supportive Care in Patients With Myelodysplastic Syndromes

SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen® Versus Supportive Care in Patients With Myelodysplastic Syndromes

Astex Drug Candidates to be Presented at the 2008 American Society of Clinical Oncology Annual Meeting

Astex Drug Candidates to be Presented at the 2008 American Society of Clinical Oncology Annual Meeting

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, that Causes Tumor Regression in AML Xenograft Models

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, that Causes Tumor Regression in AML Xenograft Models